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Escaping NK cells and recruiting neutrophils: how Morgana/NF-κB axis promotes metastasis 
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Cancer cells escape immune surveillance and induce immune cell aberrant activation to support 
tumour growth and progression. We recently reported that Morgana/NF-κB axis in breast cancer cells 
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Metastatic breast cancer is the second leading cause of cancer death in women. Despite the advance 
in diagnostic methods, the mortality for this cancer remains high. Patient death results entirely from 
metastasis formation in distant organs. 10-15% of patients have an aggressive tumour and develop 
metastasis within 3 years (1). Understanding the molecular pathways activated or de-regulated in 
cancer cells becomes fundamental to study and block cancer progression. Numerous genes are 
involved in this complex process that includes several steps starting from tumour cell proliferation, 
migration, vessel invasion, resistance from anoikis, extravasation and finally colonization of distant 
organs. Morgana is a protein ubiquitary expressed and essential for embryonic development and 
involved in tumorigenesis  (2). Morgana is frequently overexpressed in aggressive and chemo 
resistant breast tumours (as triple negative breast tumours) and it positively correlates with tumour 
grade, proliferative capacity, and lymph node involvement (3,4). Tumour progression and metastasis 
formation are strongly influenced by bidirectional communication between cancer cells and cells 
resident in the tumour microenvironment as immune system cells, fibroblasts and endothelial cells 
(5). In our recent work, we demonstrated how the axis Morgana-NF-κB can control and mediate the 
cross-talk between tumour and cell microenvironment (6). 
High Morgana expression levels in cancer cells can shape immune cell recruitment both in the tumour 
and in distant organs site of metastasis. In particular, we show that in the first phases of tumour growth 
Morgana inhibits Natural Killer (NK) cell recruitment. Several mechanisms can be used by tumour 
cells to escape immunosorveillance mediated by NK cells, in fact most tumours retained expression 
of MHC class I or tumours themselves can secrete immunomodulatory molecules specifically 
compromising NK activity (7). High Morgana levels in breast cancer cells induce MHC class I 
expression, leading to NK inhibition and immunoevasion (6). Looking at immune system cell 
recruitment in later phases of tumour progression, a significant reduction of neutrophils was observed 
in low Morgana tumours. Emerging evidences indicate that chemokine produced by the tumour can 
polarize neutrophils toward a pro-tumour phenotype, able to promote primary tumour growth and 
spread (8). The explanation of this differential immune system cell recruitment in the primary tumour 
resides in the ability of Morgana to control the activation of one of the most studied transcription 
factor: NF-κB. NF-κB represents a central player in inflammation, stress response, cell differentiation 
and proliferation. It controls the expression of a huge variety of target genes such as cytokines, growth 
factors, adhesion molecules, intracellular signalling molecules, transcription factors as well as 
miRNAs (9). Usually NF-κB is maintained inactive in the cytosol by its inhibitor IκB (inhibitors of 
NF-κB). Upon several specific stimuli, IκB proteins are phosphorylated by the canonical IKK 
complex on two specific serines, which then act as a docking platform for the ubiquitin ligase b-
TRCP. Subsequent ubiquitination induces proteasome-mediated proteolysis of the IκB protein and, 
subsequently, NF-κB is free and capable of entering the nucleus, binding DNA and activating 
transcription. The crucial mediator of the canonical pathway able to activate NF-κB is the IKK 
complex, composed by the kinase subunits IKKα and IKKβ and the regulatory subunit IKKγ (9). In 
our work we described for the first time Morgana as a component of the IKK complex necessary to 
mediate the binding between the IKK complex and its substrate IκBα both in tumorigenic (human 
MDA-MB-231, BT549, Hela, MCF10A, MCF7, and murine 4T1 and E0771) and normal cell lines 
(293T, NIH and primary mouse embryonic fibroblasts) (6). In breast cancer models, Morgana, by 
potentiating NF-κB activation and the subsequent transcription of its target genes, favours cancer cell 
invasion and metastasis formation (Figure 1). In fact, Morgana downregulation almost completely 
abrogates MDA-MB-231, 4T1 and E0771 abilities to form metastasis. Immune system cells have an 
important role not only in promoting tumour growth and spread, but also in metastasis formation. 
Several reports demonstrated that neutrophils can localize in the lung pre-metastatic niche creating a 
favourable environment to drive metastasis initiation (10). Morgana downregulation in breast cancer 
cells, by quenching NF-κB signalling, inhibits neutrophil recruitment and the formation of the pre-
metastatic niche in the lung. Furthermore, NF-κB activation, through IκBα silencing, in cancer cells 
downregulated for Morgana totally rescues primary tumour growth, neutrophil recruitment and 
metastasis formation, demonstrating a causal role of Morgana/NF-κB axis in these events. 
Bioinformatics studies on TCGA breast cancer dataset, coupled with analysis on our cohort of 152 
breast cancer patients, confirmed a correlation between Morgana expression levels, NF-κB activation, 
neutrophils recruitment and poor survival in human breast cancer patients (6). NF-κB is frequently 
overexpressed in cancer and tumour infiltrating immune cells produce cytokines that further sustain 
NF-κB activation in cancer cells, generating a vicious cycle difficult to break down. Several NF-κB 
inhibitors have been produced but the major concern in using these molecules in cancer therapy rely 
in robust immunosuppression due to NF-κB pleiotropic functions in immune responses. In this view, 
dissecting the precise network of signals originating from NF-κB pathway and the factors responsible 
for its activation in cancer cells could open new horizons to develop druggable targets able to shut 
down the vicious cycle and to block cancer progression.  
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Figure 1. Morgana is necessary to connect the IKK complex to its substrate IκBα. The consequent 
activation of NF-κB in the primary tumour induces the production of several cytokines able to 
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